All News

26 July 2007

Actemra monotherapy demonstrates significant clinical benefit in patients with rheumatoid arthritisAntibodies

24 July 2007

MedImmune Announces Interim Phase 1 Study Results for Potential Asthma TherapyAntibodies

24 July 2007

Amorfix acheives first milestone in herapeutic ALS partnership with Biogen IdecAntibodies

21 July 2007

Avastin receives positive opinion in Europe for first-line treatment of patients with advanced lung cancerAntibodies

20 July 2007

Medarex Announces Advancement of Antibody Development by PartnerAntibodies

20 July 2007

Glenmark purchases rights to two therapeutic antibodies from ChromosAntibodies

19 July 2007

Medarex Announces Initiation by Licensing Partner of Phase III Clinical Trial for Muckle Wells SyndromeAntibodies

18 July 2007

Secondary endpoints of phase II/III study confirm clear benefits from treatment with removab(R) for patients with malignant ascitesAntibodies

17 July 2007

XOMA Initiates Phase I U.S. Trial in Type 2 Diabetes for XOMA 052, Monoclonal Antibody With Therapeutic Potential in Multiple Inflammatory DiseasesAntibodies

14 July 2007

CSL Behring Completes Enrollment for Phase III Registration Trial of Next Generation of Subcutaneous ImmunoglobulinAntibodies

13 July 2007

Phase II Study of IMC-A12 for Advanced Colorectal Cancer Has Commenced Patient EnrollmentAntibodies

13 July 2007

Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung CancerAntibodies

13 July 2007

Amgen and Daiichi Sankyo announce agreement for denosumab in JapanAntibodies

12 July 2007

Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Lung Cancer PatientsAntibodies

12 July 2007

TRACON Pharmaceuticals and Micromet Announce the Initiation of Phase 1 Clinical Trial with TRC093 (D93), a Humanized Antibody for Cancer TreatmentAntibodies

11 July 2007

Peregrine Pharmaceuticals Initiates Bavituximab Clinical Trial in HCV Patients Co-Infected With HIVAntibodies

11 July 2007

Actemra: latest phase III study shows significant improvement in symptoms of patients with rheumatoid arthritisAntibodies

10 July 2007

MacroGenics IND for West Nile Virus Monoclonal Antibody is ActiveAntibodies

3 July 2007

Lexicon Develops Antibodies that Lower Triglycerides and Cholesterol as Potential New Therapy for Heart DiseaseAntibodies

3 July 2007

Ablynx announces interim results of first nanobody (R) phase i study of ALX-0081 (anti-vWF)Antibodies

2 July 2007

Genmab announces final humax-CD4 Phase II CTCL dataAntibodies

30 June 2007

WILEX to follow FDA advice and apply for a special protocol assessment (SPA) for CA9-SCANAntibodies

30 June 2007

Genmab regains rights to HuMax-CD4Antibodies

23 June 2007

Alexion’s Soliris(TM) granted marketing approval in europe for treatment of all patients with PNHAntibodies

22 June 2007

Viragen Streamlines Research Focus and Halts Further Development of OVA(TM) SystemAntibodies

20 June 2007

Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast CancerAntibodies

19 June 2007

Vegenics Licenses From CoGenesys Antibodies Against VEGF-C for Applications Including OncologyAntibodies

16 June 2007

Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia(R) (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of TherapyAntibodies

16 June 2007

GlaxoSmithKlline and Genmab present positive Phase II results with ofatumumab in patients with rheumatoid arthritis (RA)Antibodies

16 June 2007

GlaxoSmithKlline and Genmab present positive Phase II results with ofatumumab in patients with rheumatoid arthritis (RA)Antibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Mesothelin-Targeted Immunotherapy Pipeline Review

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing